Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers worldwide using compounds from Celgene. Investigational compounds are being studied for patients with rare diseases and diseases of unmet medical need. Some of the Canadian trials include Multiple Myeloma (MM), Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML), Beta-Thalassemia, Atopic Dermatitis, Psoriatic Arthritis, Psoriasis, Ulcerative Colitis, Crohn’s Disease and Multiple Sclerosis.
Please visit the Corporate Website History page to view the timeline from our founding through our exponential growth over the past three decades.